2025开年以来，丸美生物上涨60.82%，排在涨幅榜首位；上海家化上涨46.72%，居次席；华大基因上 涨34.45%；安集科技、信立泰、韦尔股份涨逾20%；科沃斯和广联达分别上涨19.60%和18.79%；珀莱 雅、恒瑞医药涨逾17%；海大集团、兆易创新、澜起科技涨逾14%；天士力、山西汾酒、药明康德分别 上涨13.20%、12.85%和11.48%。 关注国内政策发力力度 展望后市，星石投资表示，短期来看，当前在存量资金博弈背景下，宽基指数或在当前位置保持震荡。 市场结构方面，板块间或继续保持轮动，需要等待新的主线出现。 □本报记者 王宇露 上周市场反弹，中证新华社民族品牌工程指数上涨0.94%，报1666.03点。华大基因、以岭药业、石头科 技等成分股上周表现强势。2025开年以来，丸美生物、上海家化、华大基因等成分股涨幅居前。展望后 市，机构认为，接下来市场或许会重新聚焦国内经济基本面变化，预计政策面会积极应对，市场具有中 期支撑。 多只成分股表现强势 上周市场继续反弹，上证指数上涨0.76%，深证成指上涨0.52%，创业板指上涨1.38%，沪深300指数上 涨1.12%，品牌工程指数上涨0.94% ...

此次捐赠是石家庄以岭药业与北京爱谱癌症患者基金会连续多年开展的公益项目之一。作为中医药领域 的爱心企业，以岭药业始终践行"继承创新、造福人类"的宗旨，持续关注癌症患者群体需求。北京爱谱 癌症患者基金会则以"科学抗癌、关爱生命"为理念，长期致力于改善癌症患者生存质量。双方此次携 手，通过邵阳市癌症康复协会精准对接需求，将药品送至亟需帮助的会员手中。 2025年5月7日上午9时，邵阳市癌症康复协会办公室内暖意融融，一场充满温情的公益药品捐赠仪式在 此举行。石家庄以岭药业（002603）股份有限公司联合北京爱谱癌症患者基金会，向邵阳市癌症康复协 会捐赠330大盒总价值52.9万元的参灵蓝胶囊，惠及330名癌症康复会员，为患者群体送去了健康希望与 社会关爱。 公益延续显担当，爱心药企再行动 多方聚力抗病魔，共筑康复新希望 有序分发惠民生，温情传递暖人心 捐赠仪式当天，协会全体领导和骨干早早到场筹备，会员们有序排队等候。分发过程中，协会负责人逐 一核对名单，耐心讲解药品用法，并叮嘱患者遵医嘱科学用药。领到药品的会员们难掩激动之情，一位 年过六旬的肺癌康复患者表示："这些药品价格昂贵，我们普通家庭长期负担困难。感谢企业和 ...

Group 1: Company Performance - In Q1 2025, the company achieved a revenue of 2.358 billion yuan, a year-on-year decline of 6.52% [5] - The net profit attributable to shareholders was 326 million yuan, an increase of 7.25% year-on-year [10] - The operating cash flow reached 340 million yuan, showing a significant increase of 190.67% [5] Group 2: R&D and Innovation - The company has maintained a continuous increase in R&D investment, having launched 5 innovative traditional Chinese medicines in the past four years [10] - Currently, there are 17 innovative patented traditional Chinese medicines covering seven major disease areas [3] - The company is focusing on enhancing its core technological innovation capabilities and optimizing its marketing system to maintain stable product gross margins [9] Group 3: Market Strategy - The company plans to expand the market for its core product, Lianhua Qingwen, by exploring new application scenarios and implementing a comprehensive brand marketing strategy [6] - Lianhua Qingwen has obtained approvals in over 30 countries and regions, with efforts to enhance its brand influence overseas [6] - Future product development will focus on respiratory, endocrine, digestive, gynecological, and pediatric diseases [6] Group 4: Policy and Industry Outlook - The Chinese government is promoting the development of traditional Chinese medicine (TCM) through various policies, including the "14th Five-Year Plan for TCM Development" [8] - The government has emphasized the importance of TCM in disease prevention, treatment, and health maintenance, which is expected to drive industry growth [7] - The overall policy environment is favorable for the high-quality development of the TCM industry, supporting innovation and structural optimization [8] Group 5: Investor Relations and Value Management - The company aims to align market value with intrinsic value through transparent information disclosure and effective investor relations management [9] - A stable and high-quality investor base is being established to maximize overall company benefits and shareholder wealth [9] - The company has a structured plan for sustainable and scientific returns to investors, considering multiple factors such as operational conditions and development goals [2]

Core Viewpoint - The article highlights the resilience and growth of Yiling Pharmaceutical, a leading innovative traditional Chinese medicine company, following a challenging financial period, supported by favorable national policies and a strong focus on research and development. Financial Performance - In 2024, Yiling Pharmaceutical reported revenue of 6.513 billion yuan with a net loss of 0.725 billion yuan, but in Q1 2025, the company achieved revenue of 2.358 billion yuan and a non-net profit of 0.325 billion yuan, reflecting a year-on-year growth of 11.23% [2][3] - The company’s gross margin in Q1 2025 was 53.82%, an increase of 2.34 percentage points year-on-year, while the net margin was 13.82%, up by 1.85 percentage points [2][3] - Operating cash flow improved significantly, reaching 0.34 billion yuan in Q1 2025, nearly doubling the net profit for the same period [3] Debt and Receivables Management - By the end of 2024, accounts receivable stood at 1.225 billion yuan, down by 50% from the beginning of the year, while total liabilities decreased by 43.75% to 3.117 billion yuan [3] - The accounts receivable turnover days decreased to 55 days, down by 35 days year-on-year, indicating improved cash collection efficiency [3] Research and Development - Yiling Pharmaceutical's R&D investment exceeded 0.9 billion yuan in 2024, accounting for 13.9% of revenue, positioning the company as a leader in the industry [4][5] - Over the past six years, the cumulative R&D investment has approached 5 billion yuan, consistently exceeding industry averages [5] - As of the end of 2024, the company held 884 effective patents and had launched 17 patented traditional Chinese medicines covering eight major clinical disease systems [6][7] Product Development and Market Position - The company has received approval for new drugs targeting cardiovascular and respiratory diseases, with several products included in the national medical insurance directory [7][10] - Yiling Pharmaceutical is actively expanding its product portfolio, with ongoing clinical trials for six traditional Chinese medicines and over a hundred formulations in development [7][8] Policy Support and Industry Trends - The company benefits from supportive national policies aimed at revitalizing traditional Chinese medicine, including the inclusion of its products in the national medical insurance directory [10][11] - Yiling Pharmaceutical is also embracing digital transformation to enhance operational efficiency, completing significant research projects published in top medical journals [11] Strategic Vision - The company is evolving from a traditional medicine manufacturer to a health solution provider, aligning with national goals for high-quality development in the pharmaceutical industry [13]

Group 1: Conference Overview - The 2025 World Brand Moganshan Conference was held in Deqing, Zhejiang, focusing on the theme of "openness, cooperation, and win-win" to promote Chinese brands globally [1] - The conference highlighted the importance of traditional Chinese medicine (TCM) as a key to unlocking Chinese civilization and emphasized the supportive policies for the TCM industry since the 18th National Congress of the Communist Party [1] Group 2: Company Profile - Yiling Health, a subsidiary of Yiling Pharmaceutical, is dedicated to the health industry and embodies the cultural heritage of TCM while driving innovation [2] - The company has established a comprehensive health management system that integrates medicine, health, and wellness, emphasizing the shift from treatment to prevention [2] Group 3: Product Development - Yiling Health has developed a series of products based on the "Eight Principles of TCM Health Preservation," which include "Tongluo," "Yangjing," "Dongxing," and "Jingshen" [3][4][5] - The company has launched various health products, such as the "Tongluo Six Immortals" series, which addresses chronic diseases and promotes overall wellness [3] Group 4: Innovative Beverage Products - Yiling Health's herbal beverages, such as "Yimeng" and "Jinliwang," have gained popularity, becoming the sponsored drinks at the Moganshan Conference [6][8] - These beverages utilize TCM ingredients to address health concerns like blood sugar and sleep quality, aligning with consumer trends towards natural foods [6][8] Group 5: Market Strategy and Expansion - The company is leveraging the global health consumption upgrade to create a cooperative ecosystem, collaborating with various industries to expand its market reach [9] - Yiling Health aims to enhance its brand presence through a comprehensive online and offline operational matrix, targeting over 100 billion online exposures and gaining over 500,000 new users by 2023-2024 [10]

Group 1 - The 2025 World Brand Moganshan Conference was held in Deqing, Zhejiang, where Yiling Pharmaceutical was awarded the title of "Brand Innovation Pioneer" [1] - Yiling Pharmaceutical is recognized as a leading innovative traditional Chinese medicine (TCM) company, focusing on overseas brand development with the core philosophy of "inheritance and innovation" [3] - The company has developed 17 innovative patented TCM products targeting major diseases such as cardiovascular diseases, respiratory diseases, tumors, diabetes, neurological diseases, and urinary system diseases [3] Group 2 - Yiling Pharmaceutical's research shows that Tongxinluo capsules can reduce the risk of acute myocardial infarction death by 30% and the risk of recurrence by 74% [4] - The company has published its research findings in prestigious international medical journals, enhancing its credibility and market trust [4] - The innovative TCM product Bazibu Shen capsules has been shown to effectively intervene in 10 internationally recognized aging mechanisms, contributing positively to addressing the challenges of population aging [4] Group 3 - The report highlights Yiling Pharmaceutical's efforts to align TCM efficacy with international standards through evidence-based medicine, enhancing the global recognition of TCM [5] - The company utilizes modern medical language to interpret traditional wisdom, thereby increasing TCM's influence in the global health sector [5] - This is the fourth consecutive year that the report on the overseas communication capabilities of Chinese enterprises has been published, analyzing data from approximately 3,000 overseas mainstream media and social media platforms [5]

Core Insights - The article emphasizes the growing global recognition of Traditional Chinese Medicine (TCM) and its integration into modern health needs, showcasing the potential of TCM as a strategic resource in the global health industry [1][8] - Yiling Health is leveraging TCM culture and innovative product development to meet contemporary health demands, particularly through its unique product offerings and operational strategies [7][8] Group 1: TCM Cultural Integration - Yiling Health is deeply rooted in TCM culture and aims to merge traditional wisdom with modern health requirements, as demonstrated at the 2025 World Brand Moganshan Conference [1] - The company promotes the TCM preventive health concept of "treating before illness" and emphasizes the holistic approach of TCM, which addresses modern health challenges [1][2] Group 2: Product Development and Innovation - Yiling Health has developed a diverse product matrix based on the "Tongluo Health Eight Principles," which combines TCM wisdom with modern life sciences, focusing on circulation, nutrition, exercise, and mental health [2][3] - The company has created over a hundred product concepts and formulations targeting 18 common health scenarios, showcasing its strong R&D capabilities [3] Group 3: Market Trends and Consumer Demand - The rise of herbal health and the concept of "food as medicine" are becoming mainstream, with products like Yiling Health's plant-based beverages gaining popularity among health-conscious consumers [4][6] - The company's flagship products, Yimeng and Jinliwang, have achieved significant sales milestones, with Yimeng surpassing 100 million in sales in its first year [6] Group 4: Operational Strategies - Yiling Health has established a comprehensive operational system that includes online and offline sales strategies, collaborating with major e-commerce platforms and leveraging social media for brand exposure [7] - The company has successfully integrated technology and innovation into its operations, resulting in over 10 billion online exposures and the acquisition of more than 500,000 new users in 2023-2024 [7] Group 5: Future Outlook - Yiling Health aims to continue exploring the depths of TCM culture while innovating its products and services, contributing to the promotion of Chinese brands and TCM culture on a global scale [8]

Group 1 - The core initiative of Yiling Pharmaceutical is to promote the "Quality China" construction and high-quality development by enhancing brand recognition and storytelling for Chinese brands, particularly in the context of the upcoming "China Brand Day" in 2025 [3] - Yiling Pharmaceutical has launched the "5·10 Yiling Brand Month" series of activities in collaboration with nearly a hundred well-known chain pharmacies across the country, focusing on the theme "Technology Empowers Health, Brand Leads the Future" [3][4] - The activities will include public welfare science popularization, chronic disease management, and digital services to improve public health literacy and contribute positively to the construction of a healthy China [3][4] Group 2 - During the "5·10 Yiling Brand Month," Yiling Pharmaceutical will integrate quality medical resources through a multi-dimensional approach, including online science popularization and offline services, to provide comprehensive health service experiences for consumers [4] - The initiative will involve expert online live broadcasts and offline health screenings and consultations for chronic diseases, promoting the concept of "early screening, early diagnosis, early intervention" [4] - Yiling Pharmaceutical will collaborate with well-known chain pharmacies to conduct public health science roadshows across the country, aiming to enhance public access to health knowledge and services [4] Group 3 - Yiling Pharmaceutical has established a unique technological core competitiveness through the systematic construction of the theory of collateral diseases, which has led to significant technological innovations and the completion of multiple major projects [5][6] - The company has received six national science and technology awards and has developed patented new drugs for prevalent and major diseases, gaining recognition from clinical experts and patients [6] - Yiling's products, such as Lianhua Qingwen capsules and Tongxinluo capsules, have been approved for sale in over 50 countries and regions, showcasing the global reach of traditional Chinese medicine [6] Group 4 - As a national key high-tech enterprise, Yiling Pharmaceutical adheres to the principle of "inheritance and innovation for the benefit of humanity," actively engaging in social responsibility initiatives [7] - The company has achieved a water resource reuse rate of 97% through clean production and low-carbon energy practices, contributing to green development [7] - Yiling Pharmaceutical has created over 60 high-standard Chinese medicinal herb bases across more than 20 provinces, providing numerous job opportunities and revitalizing rural industries [7]

Group 1 - The "2025 China Brand Day Ninth Brand Development Co-Creation Conference" focused on themes of fair competition and brand consumption, gathering industry leaders and experts to discuss brand innovation and sustainable development [1] - The conference highlighted the transformation of Chinese brands from "Made in China" to "Created in China," emphasizing the shift from product output to cultural output [2] - The demand for traditional Chinese medicine (TCM) is growing due to increased health awareness, but TCM brands face challenges in distinguishing themselves in modern medical competition and international markets [4] Group 2 - Cultural confidence is a lasting force in national development, with TCM recognized globally as a treasure of Chinese civilization, leading to increased international attention and validation of its theoretical value [5] - Yiling Pharmaceutical, a leading innovative TCM company, has developed the Ba Zi Bu Shen capsule, which meets international scientific standards and promotes the integration of TCM evaluation systems with global practices [5] - The Ba Zi research team has collaborated with international medical research institutions, publishing nearly 20 high-quality SCI articles to enhance the brand's presence among professional audiences [5] Group 3 - Chinese brands, including TCM, are gaining recognition on the global stage, with Ba Zi Bu Shen approved for sale in eight countries, including Canada and Singapore, and available on major cross-border platforms [7] - The international success of TCM products like Ba Zi Bu Shen contributes to the promotion of TCM's influence abroad and fosters dialogue between Eastern and Western medicine [7]

证券代码：002603 证券简称：以岭药业 公告编号：2025-021 石家庄以岭药业股份有限公司（以下简称"公司"）于2025年5月7日接到保 荐机构中国国际金融股份有限公司（以下简称"中金公司"）《关于更换石家庄 以岭药业股份有限公司持续督导保荐代表人的说明》。中金公司原委派的保荐代 表人贾义真先生和张磊先生因工作安排，不再担任公司的持续督导保荐代表人。 中金公司决定指派李胤康先生、韩佰洋先生接替贾义真先生、张磊先生继续履行 对公司持续督导的相关职责和义务。 此次保荐代表人变更后，公司持续督导保荐代表人为李胤康先生和韩佰洋 先生，持续督导期至中国证券监督管理委员会和深圳证券交易所规定的持续督 导义务结束为止。 特此公告。 石家庄以岭药业股份有限公司 董事会 石家庄以岭药业股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 5 月 10 日 附： 李胤康先生简历 李胤康先生，A股保荐代表人，金融学硕士，现就职于中金公司投资银行 部，曾负责和参与的项目包括恒润达生科创板IPO、泽璟制药科创板增发、怡 和 ...